MDACC Study No:2006-0803 ( NCT No: NCT00410982)
Title:Gemcitabine combined with busulfan and melphalan, with hematopoietic cell transplantation, for patients with poor-prognosis advanced lymphoid malignancies
Principal Investigator:Yago Nieto
Treatment Agent:Busulfan; Gemcitabine; Melphalan
Study Status:Terminated
Study Description:The goal of this clinical research study is to find the highest tolerated dose
of gemcitabine that can be given with busulfan and melphalan. The safety of
this drug combination will also be studied.
Hide details for General InformationGeneral Information

Disease Group:Lymphoma; Myeloma
Phase of Study:Phase I/Phase II
Treatment Agents:Busulfan
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:30 days post transplant, and will include inpatient and out patient care during
this time period.
Supported By:N/A
Return Visit:Study will terminate on transplant day +100. Patients will subsequently
monitored at the discretion of their physicians.
Home Care:IV fluids, etc. as determined by patient's clinical status.

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Yago Nieto
Dept:Stem Cell Transplantation and Cellular Therapy
For Clinical Trial Enrollment:713-792-8750
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults